{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:32:38Z","timestamp":1777185158694,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,15]],"date-time":"2027-01-15T00:00:00Z","timestamp":1799971200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI158571"],"award-info":[{"award-number":["P01AI158571"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI181968"],"award-info":[{"award-number":["U19AI181968"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI153064"],"award-info":[{"award-number":["R01AI153064"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.it.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:29:00Z","timestamp":1762406940000},"page":"43-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Coming of age: mRNA vaccines for orthoflaviviruses"],"prefix":"10.1016","volume":"47","author":[{"given":"Fahima","family":"Akther","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-8961","authenticated-orcid":false,"given":"David R.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2025.10.005_bb0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.vaccine.2012.11.015","article-title":"Immune evasion strategies of flaviviruses","volume":"31","author":"Ye","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2025.10.005_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/antib12010018","article-title":"Serological cross-reactivity in zoonotic flaviviral infections of medical importance","volume":"12","author":"da Silva","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.it.2025.10.005_bb0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0140-6736(08)60238-X","article-title":"Pathogenic flaviviruses","volume":"371","author":"Gould","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.it.2025.10.005_bb0020","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/nm1144","article-title":"Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses","volume":"10","author":"Mackenzie","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.chom.2009.04.001","article-title":"Pathogenesis of flavivirus infections: using and abusing the host cell","volume":"5","author":"Fernandez-Garcia","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.it.2025.10.005_bb0030","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1080\/21505594.2021.1996059","article-title":"Pathogenesis and virulence of flavivirus infections","volume":"12","author":"van Leur","year":"2021","journal-title":"Virulence"},{"key":"10.1016\/j.it.2025.10.005_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100188","article-title":"Flaviviruses and the traveler: around the world and to your stage. a review of West Nile, yellow fever, Dengue, and Zika viruses for the practicing pathologist","volume":"36","author":"Hale","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.it.2025.10.005_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.it.2025.10.005_bb0045","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v9.31669","article-title":"Estimated Zika virus importations to Europe by travellers from Brazil","volume":"9","author":"Massad","year":"2016","journal-title":"Glob. Health Action"},{"key":"10.1016\/j.it.2025.10.005_bb0050","first-page":"539","article-title":"Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus","volume":"20","author":"Daep","year":"2014","journal-title":"J. Neuro Virol."},{"key":"10.1016\/j.it.2025.10.005_bb0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/vaccines9020148","article-title":"mRNA vaccines against flaviviruses","volume":"9","author":"Wollner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.10.005_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2013 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2025.10.005_bb0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2025.10.005_bb0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2013 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2025.10.005_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101398","article-title":"Research progress of mosquito-borne virus mRNA vaccines","volume":"33","author":"Sun","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.it.2025.10.005_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-018-0072-6","article-title":"Incorporation of NS1 and prM\/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein","volume":"3","author":"Liu","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.it.2025.10.005_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.it.2025.10.005_bb0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.it.2025.10.005_bb0095","article-title":"Flaviviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines","volume":"13","author":"Pan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1257024","article-title":"Mosquito-borne flaviviruses and type I interferon: catch me if you can!","volume":"14","author":"Zoladek","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.it.2025.10.005_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.it.2025.10.005_bb0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/bfgp\/elab027","article-title":"Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design","volume":"20","author":"Cai","year":"2021","journal-title":"Brief. Funct. Genomics"},{"key":"10.1016\/j.it.2025.10.005_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102079","article-title":"A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines","volume":"298","author":"Phan","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2025.10.005_bb0120","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Slon-Campos","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/vaccines7030096","article-title":"Immunogenicity and protection efficacy of a naked self-replicating mRNA-based Zika virus vaccine","volume":"7","author":"Zhong","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.10.005_bb0130","article-title":"A Dengue virus serotype 1 mRNA\u2013LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner Clayton","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.10.005_bb0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.virs.2022.07.003","article-title":"A multiple-target mRNA\u2013LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice","volume":"37","author":"He","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.it.2025.10.005_bb0140","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3389\/fimmu.2019.01424","article-title":"A modified mRNA vaccine targeting immunodominant NS epitopes protects against Dengue virus infection in HLA Class I transgenic mice","volume":"10","author":"Roth","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0145","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA\u2013LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.it.2025.10.005_bb0150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.it.2025.10.005_bb0155","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.it.2025.10.005_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0165","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2025.10.005_bb0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.it.2025.10.005_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.it.2025.10.005_bb0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41587-024-02306-z","article-title":"Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency","volume":"43","author":"McGee","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.it.2025.10.005_bb0185","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2025.10.005_bb0190","doi-asserted-by":"crossref","DOI":"10.1093\/narmme\/ugae004","article-title":"Self-amplifying RNAs generated with the modified nucleotides 5-methylcytidine and 5-methyluridine mediate strong expression and immunogenicity in vivo","volume":"1","author":"Azizi","year":"2024","journal-title":"NAR Mol. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","article-title":"Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.it.2025.10.005_bb0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41587-023-02101-2","article-title":"First self-amplifying mRNA vaccine approved","volume":"42","author":"Anon","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.it.2025.10.005_bb0205","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.it.2025.10.005_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.it.2025.10.005_bb0215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri3247","article-title":"Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination","volume":"12","author":"Desmet","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0220","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife\u2019s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B cells as antigen presenting cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0230","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0235","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","article-title":"Yellow fever virus: knowledge gaps impeding the fight against an old foe","volume":"26","author":"Douam","year":"2018","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.it.2025.10.005_bb0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.it.2025.10.005_bb0245","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/07391102.2021.2024253","article-title":"Modeling mRNA-based vaccine YFV.E1988 against yellow fever virus E-protein using immuno-informatics and reverse vaccinology approach","volume":"41","author":"Khan","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.it.2025.10.005_bb0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-023-00629-7","article-title":"Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models","volume":"8","author":"Medina-Mag\u00fces","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.it.2025.10.005_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1569454","article-title":"A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses","volume":"16","author":"Battisti","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0260","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika","volume":"26","author":"Erasmus","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2025.10.005_bb0265","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMc1608612","article-title":"Zika virus infection and associated neurologic disorders in Brazil","volume":"376","author":"Oliveira","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002611","article-title":"Sexual transmission of Zika virus and other flaviviruses: a living systematic review","volume":"15","author":"Counotte","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.it.2025.10.005_bb0275","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.it.2025.10.005_bb0280","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/vaccines10111816","article-title":"Current advances in Zika vaccine development","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.10.005_bb0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-018-0061-9","article-title":"Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation","volume":"3","author":"Barrett","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.it.2025.10.005_bb0290","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine mediated protection against Zika virus-induced congenital disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.it.2025.10.005_bb0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.it.2025.10.005_bb0300","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3390\/vaccines9121464","article-title":"mRNA vaccine protects against Zika virus","volume":"9","author":"Medina-Mag\u00fces","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.10.005_bb0305","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2025.10.005_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent Zika virus vaccine using self-amplifying messenger RNA","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.it.2025.10.005_bb0315","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.it.2025.10.005_bb0320","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.it.2025.10.005_bb0325","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.it.2025.10.005_bb0330","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.it.2025.10.005_bb0335","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1473-3099(16)30168-2","article-title":"The risks behind Dengvaxia recommendation","volume":"16","author":"Aguiar","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.it.2025.10.005_bb0340","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2019.0234","article-title":"Serostatus testing and dengue vaccine cost-benefit thresholds","volume":"16","author":"Pearson","year":"2019","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.it.2025.10.005_bb0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/vaccines13050483","article-title":"Dengue vaccine development and deployment into routine immunization","volume":"13","author":"Wilder-Smith","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.it.2025.10.005_bb0350","doi-asserted-by":"crossref","first-page":"e1160","DOI":"10.1093\/infdis\/jiaf145","article-title":"Estimated efficacy of TAK-003 against asymptomatic dengue infection in children and adolescents participating in the DEN-301 Trial in Asia Pacific and Latin America","volume":"231","author":"El Hindi","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.it.2025.10.005_bb0355","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41591-025-03771-y","article-title":"Efficacy, public health impact and optimal use of the Takeda dengue vaccine","volume":"31","author":"Cracknell Daniels","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2025.10.005_bb0360","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41541-024-00967-0","article-title":"Long term T cell response and safety of a tetravalent dengue vaccine in healthy children","volume":"9","author":"Mandaric","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.it.2025.10.005_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127216","article-title":"Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue","volume":"57","author":"Kumari","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2025.10.005_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384442","article-title":"Potential of mRNA-based vaccines for the control of tick-borne pathogens in one health perspective","volume":"15","author":"Gonz\u00e1lez-Cueto","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0375","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1080\/21645515.2016.1218098","article-title":"Tick-borne encephalitis: what travelers should know when visiting an endemic country","volume":"12","author":"Chrdle","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.it.2025.10.005_bb0380","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fpubh.2017.00342","article-title":"Powassan virus \u2013 a new reemerging tick-borne disease","volume":"5","author":"Fatmi","year":"2017","journal-title":"Front. Public Health"},{"key":"10.1016\/j.it.2025.10.005_bb0385","article-title":"A comprehensive neurological perspective on tick-borne flaviviruses, with emphasis on Powassan virus","volume":"11","author":"Fareed","year":"2024","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.it.2025.10.005_bb0390","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2025.10.005_bb0395","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/v14061121","article-title":"Protective immune responses induced by an mRNA\u2013LNP vaccine encoding prM-E proteins against Japanese encephalitis virus infection","volume":"14","author":"Chen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.it.2025.10.005_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1472824","article-title":"An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.it.2025.10.005_bb0405","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.immuni.2020.09.001","article-title":"Affinity-restricted memory B cells dominate recall responses to heterologous flaviviruses","volume":"53","author":"Wong","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.it.2025.10.005_bb0410","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fimmu.2020.00334","article-title":"Cross-reactive immunity among flaviviruses","volume":"11","author":"Rathore","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2025.10.005_bb0415","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.01826-10","article-title":"An in-depth analysis of original antigenic sin in dengue virus infection","volume":"85","author":"Midgley","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2025.10.005_bb0420","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41565-025-01958-5","article-title":"Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications","volume":"20","author":"Vadovics","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.it.2025.10.005_bb0425","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41564-024-01726-6","article-title":"mRNA-encoded Cas13 can be used to treat dengue infections in mice","volume":"9","author":"Basu","year":"2024","journal-title":"Nat. Microbiol."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490625002492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490625002492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:18:59Z","timestamp":1768493939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490625002492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1471490625002492"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2025.10.005","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coming of age: mRNA vaccines for orthoflaviviruses","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}